Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Clinical trial NCT03539536 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03539536
- Sponsor
- AbbVie
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-10
- Primary completion
- 2026-07-01
- Enrollment
- 270
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.